The role of cytokines in experimental autoimmune encephalomyelitis

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 5, 2000, Pages 389-398

  Bettelli, Estelle ^a   Nicholson, Lindsay B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis; Myelin oligodenodrocyte protein; Proteolipid protein; Review

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; MULTIPLE SCLEROSIS; REVIEW; TH1 CELL;

CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERFERON TYPE II; INTERLEUKINS; MULTIPLE SCLEROSIS; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034567274     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. AHN H. J., MARUO S., TOMURA M., MU J., HAMAOKA T., NAKANISHI K., CLARK S., KURIMOTO M., OKAMURA H. and FUJIWARA H. (1997): A mechanism underlyind synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J. Immunol., 159, 2125-2131.
2. ALVORD E. C., KIES M. W. and SUCKLING A. J. (1984): Experimental allergic encephalomyelitis: A useful model for multiple sclerosis. Liss, New York.
3. BEGOLKA W. S., VANDERLUG C. L., RAHBE S. M. and MILLER S. D. (1998): Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol., 161, 4437-4446.
4. BETTELLI E., DAS M. P., HOWARD E. D., WEINER H. L., SOBEL R. A. and KUCHROO V. K. (1998): IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10-and IL-4-deficient and transgenic mice. J. Immunol., 161, 3299-3306.
5. BILLIAU A., HEREMANS H., VANDEKERCKHOVE F., DIJKMANS R., SOBIS H., MEULEPAS E. and CARTON H. (1988): Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J. Immunol., 140, 1506-1510.
6. CANNELLA B., GAO Y. L., BROSNAN C. and RAINE C. S. (1996): IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J. Neurosci. Res., 45, 735-746.
7. CHANG T. T., JABS C., SOBEL R. A., KUCHROO V. K. and SHARPE A. H. (1999): Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med., 190, 733-740.
8. CHEN Y., KUCHROO V. K., INOBE J., HAFLER D. A. and WEINER H. L. (1994): Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science, 265, 1237-1240.
9. CHIANG C. S., POWELL H. C., GOLD L. H., SAMIMI A. and CAMPBELL I. L. (1996): Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J. Clin. Invest., 97, 1512-1524.
10. DERYNCK R. (1994): Transforming growth factor-beta. In Thomson A. W. (ed.): The cytokine handbook. Academic Press Ldt, London, 319-342.
11. DIAB A., ZHU J., XIAO B. G., MUSTAFA M. and LINK H. (1997): High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J. Neuropathol. Exp. Neurol., 56, 641-650.
12. DUONG T. T., ST. LOUIS J., GILBERT J. J., FINKELMAN F. D. and STREJAN G. H. (1992): Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passibely induced experimental allergic encephalomyelitis in the SJL/J mouse. J. Neuroimmunol., 36, 105-115.
13. ENCINAS J. A., WICKER L. S., PETERSON L. B., MUKASA A., TEUSCHER C., SOBEL R., WEINER H. L., SEIDMAN C. E., SEIDMAN J. G. and KUCHROO V. K. (1999): QTL influence autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing I12 (letter). Nat. Genet., 21, 158-160.
14. ENGELHARDT B., DIAMANSTEIN T. and WERKERLE H. (1989): Immunotherapy of experimental autoimmune encephalomyelitis (EAE): Differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE in the Lewis rat. J. Autoimmun., 2, 61-73.
15. ESPEVIK T., FIGARI I. S., SHALABY M. R., LACKIDES G. A., LEWIS G. D., SHEPARD H. M. and PALLADINO M. A. JR. (1987): Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J. Exp. Med., 166, 571-576.
16. FREI K., EUGSTER H. P., BOPST M., CONSTANTINESCU C. S., LAVI E. and FONTANA A. (1997): Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med., 185, 2177-2182.
17. GIJBELS K., BROCKE S., ABRAMS J. S. and STEINMAN L. (1995): Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is as-sociated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol. Med., 1, 795-805.
18. GOVERMAN J., WOODS A., LARSON L., WEINER L. P., HOOD L. and ZALLER D. M. (1993): Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous, autoimmunity. Cell, 72, 551-560.
19. GREWAL I. S., FOELLMER H. G., GREWAL K. D., XU J., HARDARDOTTIR F., BARON J. L., JANEWAY C. A. J. and FLAVEL R. A. (1996): Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science, 273, 1864-1867.
20. GROUX H., O'GARRA A., BIGLER M., ROULEAU M., ANTONENKO S., DE VRIES J. E. and RONCARLO M. G. (1997): A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevention colitis. Nature, 389, 737-742.
21. HOWARD M., FARRAR J., HILFIKER M., JOHNSON B., TAKATSU K., HAMAOKA T. and PAUL W. E. (1982): Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J. Exp. Med., 155, 914-923.
22. HSIEH C. S., HEIMBERGER A. B., GOLD J. S., O'GARRA A. and MURPHY K. M. (1992): Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc. Natl. Acad. Sci. USA, 89, 6065-6069.
23. HSIEH C. S., MACATONIA S. E., TRIPP C. S., WOLF S. F., O'GARRA A. and MURPHY K. M. (1993): Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science, 260, 547-549.
24. INOBE J. I., CHEN Y. and WEINER H. L. (1996): In vivo administration of IL-4 induces TGF-beta-producing cells and protects animals from experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci., 78, 390-392.
25. ISSAZADEH S., LJUNGDAHL A., HOJEBERG B., MUSTAFA M. and OLSSON T. (1995): Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J. Neuroimmunol., 61, 205-212.
26. ISSAZEDEH S., LORENTZEN J. C., MUSTAFA M. I., HOJEBERG B., MUSSENER A. and OLSSON T. (1996): Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. J. Neuroimmunol., 69, 103-115.
27. JACOBS C. A., BAKER P. E., ROUX E. R., PICHA K. S., TOIVOLA B., WAUGH S. and KENNEDY M. K. (1991): Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J. Immunol., 146, 2983-2989.
28. JOHNS L. D., FLANDERS K. C., RANGES G. E. and SRIRAM S. (1991): Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol., 147, 1792-1796.
29. KEHRL J. H., WAKEFIELD L. M., ROBERTS A. B., JAKOWLEW S., ALVAREZ-MON M., DERYNCK R., SPORN M. B. and FAUCI A. S. (1986): Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med., 163, 1037-1050.
30. KENNEDY M. K., TORRANCE D. S., PICHA K. S. and MOHLER K. M. (1992): Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol., 149, 2496-2505.
31. KHOURY S. J., HANCOCK W. W. and WEINER H. L. (1992): Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med., 176, 1355-1364.
32. KIVISAKK P., MATUSEVICIUS D., HE B,. SODERSTROM M., FREDRIKSON S. and LINK H. (1998): IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clin. Exp. Immunol., 111, 193-197.
33. KORNER H., LEMCKERT F. A., CHAUDHRI G., ETTELDORF S. and SEDGWICK J. D. (1997): Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol., 27, 1973-1981.
34. KORNER H., RIMINTON D. S., STRICKLAND D. H., LEMCKERT F. A., POLLARD J. D. and SEDGWICK J. D. (1997): Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med., 186, 1585-1590.
35. KRAKOWSKI M. and OWENS T. (1996): Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol., 26, 1641-1646.
36. KROEMER G., ANDREU J. L., GONZALO J. A., GUTIERREZ-RAMOS J. C. and MARTINEZ A. C. (1991): Interleukin-2, autotolerance, and autoimmunity. Adv. Immunol., 50, 147-235.
37. KUCHROO V. K., PRABHU DAS M., BROWN J. A., RANGER A. M., ZAMVIL S. S., SOBEL R. A., WEINER H. L., NABAVI N. and GLIMCHER L. H. (1995): B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell, 80, 707-718.
38. KUHN R., RAJEWSKY K. and MULLER W. (1991): Generation and analysis of interleukin-4 deficient mice. Science, 254, 707-710.
39. KURUVILLA A. P., SHAH R., HOCHWALD G. M., LIGGITT H. D., PALLADINO M. A. and THORBECKE G. J. (1991): Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA, 88, 2918-2921.
40. LAFAILLE J. J. (1998): The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev., 9, 139-151.
41. LAFAILLE J. J., NAGASHIMA K., KATSUKI M. and TONEGAWA S. (1994): High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell, 78, 399-408.
42. LAFAILLE J. J., VAN de KEERE F., HSU A. L., BARON J. L., HAAS W., RAINE C. S. and TONEGAWA S. (1997): Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med., 186, 307-312.
43. LEONARD J. P., WALDBURGER K. E. and GOLDMAN S. J. (1995): Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med., 181, 381-386.
44. LEONARD J. P., WALDBURGER K. E. and GOLDMAN S. J. (1996): Regulation of experimental autoimmune encephalomyelitis by interleukin-12. Ann. NY Acad. Sci., 795, 216-226.
45. LIBLAU R., STEINMAN L. and BROCKE S. (1997): Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int. Immunol., 9, 799-803.
46. LIU J., MARINO M. W., WONG G., GRAIL D., DUNN A., BETTADAPURA J., SLAVIN A. J., OLD L. and BERNARD C. C. (1998): TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med., 4, 78-83.
47. MANNIE M. D., DINARELLO C. A. and PATERSON P. Y. (1987): Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating experimental autoimmune encephalomyelitis in Lewis rats. J. Immunol., 138, 4229-4235.
48. MATHISEN P. M., YU M., JOHNSON J. M., DRAZBA J. A. and TUOHY V. K. (1997): Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med., 186, 159-164.
49. MENDEL I., KATZ A., KOZAK N., BEN-NUN A. and REVEL M. (1998): Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol., 28, 1727-1737.
50. MERRILL J. E., KONO D. H., CLAYTON J., ANDO D. G., HINTON D. R. and HOFMAN F. M. (1992): Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10. PL mice [published erratum appears in Proc. Natl. Acad. Sci. USA 1992 Nov 1; 89(21): 10562]. Proc. Natl. Acad. Sci. USA, 89, 574-578.
51. MERRILL J. E., KONO D. H., CLAYTON J., ANDO D. G., HINTON D. R. and HOFMAN F. M. (1992): Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10. PL mice [published erratum appears in Proc. Natl. Acad. Sci. USA 1992 Nov 1; 89(21): 10562]. Proc. Natl. Acad. Sci. USA, 89, 574-578.
52. MICALLEF M. J., OHTSUKI T., KOHNO K., TANABE F., USHIO S., NAMBA M., TANIMOTO, TORIGOE K., FUJII M., IKEDA M., FUKUDA S. and KURIMOTO M. (1996): Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol., 26, 1647-1651.
53. MILLER A., LIDER O., ROBERTS A. B., SPORN M. B. and WEINER H. L. (1992): Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc. Natl. Acad. Sci. USA, 89, 421-425.
54. MOSMANN T. R. and SAD S. (1996): The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today, 17, 138-146.
55. NAGELKERKEN L., BLAUW B. and TIELEMANS M. (1997): IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice [published erratum appears in Int. Immunol. 1997 Nov; 9(11): 1773]. Int. Immunol., 9, 1243-1251.
56. NAGELKERKEN L., BLAUW B. and TIELEMANS M. (1997): IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice [published erratum appears in Int. Immunol. 1997 Nov; 9(11): 1773]. Int. Immunol., 9, 1243-1251.
57. NICHOLSON L. B., CARRIZOSA A. M. and KUCHROO V. K. (1998): Pathogenic versus protective repertoires in autoimmune disease: Tuning the balance. Immunologist, 6, 151-157.
58. NICHOLSON L. B. and KUCHROO V. K. (1996): Manipulation of the Th1/Th2 balance in autoimmune disease. Curr. Opin. Immunol., 8, 837-842.
59. NICHOLSON L. B., MURTAZA A., HAFLER B. P., SETTE A. and KUCHROO V. K. (1997): A T cell receptor antagonist peptide prevents autoimmune encephalomyelitis induced with multiple myelin antigens: Evidence for bystander suppression. Proc. Natl. Acad. Sci. USA, 94, 9279-9284.
60. NICHOLSON L. B., WINDHAGEN A., PRABHU DAS M., HAFLER D. A. and KUCHROO V. K. (1997): The role of immune deviation in regulation of experimental autoimmune encephalomyelitis and multiple sclerosis. In ADORINI L. (ed.): Immunoin-tervention in autoimmunity by Th1/Th2 regulation. Landes Bioscience, Austin, Texas, 105-127.
61. OKUDA Y., NAKATSUJI Y., FUJIMURA H., ESUMI H., OGURA T., YANAGIHARA T. and SAKODA S. (1995): Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J. Neuroimmunol., 62, 103-112.
62. OKUDA Y., SAKODA S., BERNARD C. C., FUJIMURA H., SAEKI Y., KISHIMOTO T. and YANAGIHARA T. (1998): IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol., 10, 703-708.
63. PANITCH H. S. and BEVER C. T. JR. (1993): Clinical trials of interferons in multiple sclerosis. What have we learned? J. Neuroimmunol., 46, 155-164.
64. POHL-KOPPE A., BALASHOV K. E., STEERE A. C., LOGIGIAN E. L. and HAFLER D. A. (1998): Identification of a T cell subset capable of both IFN-gamma and IL-10 secretion in patients with chronic Borrelia burgdorferi infection. J. Immunol., 160, 1804-1810.
65. POWELL H. C., GARRETT R. S., BRETT F. M., CHIANG C. S., CHEN E., MASLIAH E. and CAMPBELL I. L. (1999): Response of glia, mast cells and the blood brain barrier, in transgenic mice expressing interleukin-3 in astrocytes, an experimental model for CNS demyelination. Brain Pathol., 9, 219-235.
66. RACKE M. K., BONOMO A., SCOTT D. E., CANNELLA B., LEVINE A., RAINE C. S., SHEVACH E. M. and ROCKEN M. (1994): Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med., 180, 1961-1966.
67. RACKE M. K., CANNELLA B., ALBERT P., SPORN M., RAINE C. S. and MCFARLIN D. E. (1992): Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int. Immunol., 4, 615-620.
68. RACKE M. K., DHIB-JALBUT S., CANNELLA B., ALBERT P. S., RAINE C. S. and MCFARLIN D. E. (1991): Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol., 146, 3012-3017.
69. REINER S. L., WANG Z., HATAM F., SCOTT P. and LOCKSLEY R. M. (1993): Th1 and Th2 cell antigen receptors in experimental leishmaniasis. Science, 259, 1457-1460.
70. ROBINSON D:, SHIBUYA K., MUI A., ZONIN F., MURPHY E., SANA T., HARTLEY S. B., MENON S., KASTELEIN R., BAZAN F. and O'GARRA A. (1997): IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity, 7, 571-581.
71. RODRIGUEZ M., PAVELKO K. D., MCKINNEY C. W. and LEIBOWITZ J. L. (1994): Recombinant human IL-6 suppressed demyelination in a viral model of multiple sclerosis. I. Immunol., 153, 3811-3821.
72. ROMAGNANI S. (1994): Lymphokine production by human T cells in disease states. Annu. Rev. Immunol., 12, 227-257.
73. ROMANI L., MENCACCI A., GROHMANN U., MOCCI S., MOSCI P., PUCCETTI P. and BISTONI F. (1992): Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J. Exp. Med., 176, 19-25.
74. ROTT O., FLEISCHER B. and CASH E. (1994): Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol., 24, 1434-1440.
75. RUCKERT R., HERZ U., PAUS R., UNGUREANU D., POHL T., RENZ H. and BULFONE-PAUS S. (1998): IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both. Eur. J. Immunol., 28, 3312-3320.
76. RUDDLE N. H., BERGMAN C. M., MCGRATH K. M., LINGENHELD E. G., GRUNNET M. L., PADULA S. J. and CLARK R. B. (1990): An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med., 172, 1193-1200.
77. SADLACK B., LOHLER J., SCHORLE H., KLEBB G., HABER H., SICKEL E., NOELLE R. J. and HORAK I. (1995): Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliveration of CD4+ T cells. Eur. J. Immunol., 25, 3053-3059.
78. SADLACK B., MERZ H., SCHORLE H., SCHIMPL A., FELLER A. C. and HORAK I. (1993): Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell, 75, 253-261.
79. SAMOILOVA E. B., HORTON J. L. and CHEN Y. (1998): Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell. Immunol., 188, 118-124.
80. SAMOILOVA E. B., HORTON J. L., HILLARD B., LIU T. S. and CHEN Y. (1998): IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol., 161, 6480-6486.
81. SANTAMBROGIO L., HOCHWALD G. M., SAXENA B., LEU C. H., MARTZ J. E., CARLINO J. A., RUDDLE N. H., PALLADINO M. A., GOLD L. I. and THORBECKE G. J. (1993): Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J. Immunol., 151, 1116-1127.
82. SCHLUESENER H. J. (1990): Transforming growth factors type beta 1 and beta 2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-gamma and tumor necrosis factor-alpha. J. Neuroimmunol., 27, 41-47.
83. SEDER R. A., GAZZINELLI R., SHER A. and PAUL W. E. (1993): Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA, 90, 10188-10192.
84. SEDER R. A., PAUL W. E., DAVIS M. M. and FAZEKAS DE ST. GROTH B. (1992): The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cell from receptor transgenic mice. J. Exp. Med., 176, 1091-1098.
85. SEGAL B. M., DWYER B. K. and SHEVACH E. M. (1998): An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med., 187, 537-546.
86. SELMAJ K., RAINE C. S. and CROSS A. H. (1991): Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol., 30, 694-700.
87. SHAW M. K., LORENS J. B., DHAWAN A., DAL CANTO R., TSE H. Y., TRAN A. B., BONPANE C., ESWARAN S. L., BROCKE S., SARVETNICK N., STEINMAR L., NOLAN G. P. and FATHMAN C. G. (1997): Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med., 185, 1711-1714.
88. SMITH K. A. (1988): Interleukin-2: inception, impact, and implications. Science, 240, 1169-1176.
89. SOBEL R. A., GREEN J. A. and KUCHROO V. K. (1994): Autoimmune responses to myelin proteolipid protein. Neurochem. Res., 19, 915-921.
90. STEINMAN L. (1997): Some misconceptions about understanding autoimmunity through experiments with knockouts. J. Exp. Med., 185, 2039-2041.
91. SUEN W. E., BERGMAN C. M., HJELMSTROM P. and RUDDLE N. H. (1997): A critical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med., 186, 1233-1240.
92. SWAIN S. L., WEINBERG A. D., ENGLISH M. and HUSTON G. (1990): IL-4 directs the development of Th2-like helper effectors. J. Immunol., 145, 3796-3806.
93. TAGA T. and KISHIMOTO T. (1997): Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol., 15, 797-819.
94. TANUMA N., KOJIMA T., SHIN T., AIKAWA Y., KOHJI T., ISHIHARA Y. and MATSUMOTO Y. (1997): Competitive PCR quantification of pro-and anti-inflammatory cytokine mRNA in the central nervous system during autoimmune encephalomyelitis. J. Neuroimmunol., 73, 197-206.
95. The Lenercept Multiple Sclerosis Study Group (1999): TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology, 53, 457-465.
96. TRINCHIERI G. and SCOTT P. (1995): Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol., 146, 423-431.
97. TSUNAWAKI S., SPORN M., DING A. and NATHAN C. (1988): Deactivation of macrophages by transforming growth factor-beta. Nature, 334, 260-262.
98. VAN OOSTEN B. W., BARKHOF F., TRUYEN L., BORINGA J. B., BERTELSMANN F. W., VON BLOMBERG B. M., WOODY J. N., HARTUNG H. P. and POLMAN C. H. (1996): Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 47, 1531-1534.
99. VAN PARIJS L. and ABBAS A. ( 1998) : Homeostatis and self-tolerance in the immune system-turning lymphocytes off. Science, 280, 243-248.
100. WAKSMAN B. H. (1995): Multiple sclerosis. More genes versus environment. Nature, 377, 105-106.
101. WALDMANN T. A. and TAGAYA Y. (1999): The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol., 17, 19-49.
102. WALDNER H.-P., WHITTERS M. J., SOBEL R. A., COLLINS M. and KUCHROO V. K. (2000): Fulminant spontaneous autoimmunity of the central nervous system in myelin proteolipid protein specific T cell receptor transgenic mice. Proc. Natl. Acad. Sci. USA, 97, 3412-3417.
103. WEKERLE H. (1993): Experimental autoimmune encephalomyelitis as a model of immune-mediated CNS disease. Curr. Opin. Neurobiol., 3, 779-784.
104. WILDBAUM G., YOUSSEF S., GRABIE N. and KARIN N. (1998): Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol., 161, 6368-6374.
105. WILLENBORG D. O., FORDHAM S. A., COWDEN W. B. and RAMSHAW I. A. (1995): Cytokines and murine autoimmune encephalomyelitis: inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand. J. Immunol., 41, 31-41.
106. WILLENBORG D. O., FORDHAM S. A., O'BRIEN N. C., COWDEN W. B. and RAMSHAW I. A. (1998): Tumor necrosis factor-alpha and lymphotoxin alpha in the pathology of experimental autoimmune encephalomyelitis: is either one responsible or is there another ligand mediating disease. Res. Immunol., 149, 804-810.
107. ZAMVIL S. S. and STEINMAN L. (1990): The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol., 8, 579-621.
108. ZHANG B., YAMAMURA T., KONDO T., FUJIWARA M. and TABIRA T. (1997): Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med., 186, 1677-1687.